Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 399

1.

Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system.

Dalakas MC.

Ther Adv Neurol Disord. 2018 Sep 14;11:1756286418799864. doi: 10.1177/1756286418799864. eCollection 2018. Review.

2.

Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.

Hughes R, Dalakas MC, Merkies I, Latov N, L├ęger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP; FORCIDP Trial Investigators.

Lancet Neurol. 2018 Aug;17(8):689-698. doi: 10.1016/S1474-4422(18)30202-3. Epub 2018 Jul 9. Erratum in: Lancet Neurol. 2018 Nov;17(11):933.

PMID:
30001923
3.

Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy.

Alexopoulos H, Akrivou S, Mastroyanni S, Antonopoulou M, Dinopoulos A, Giorgi M, Konstantinou K, Kouremenos E, Lariou M, Naoumis D, Pavlidou E, Pavlou E, Voudris K, Vlachoyiannopoulos P, Dalakas MC.

Ther Adv Neurol Disord. 2018 Apr 23;11:1756286418768778. doi: 10.1177/1756286418768778. eCollection 2018.

4.

Myositis: Are autoantibodies pathogenic in necrotizing myopathy?

Dalakas MC.

Nat Rev Rheumatol. 2018 May;14(5):251-252. doi: 10.1038/nrrheum.2018.54. Epub 2018 Apr 12. No abstract available.

PMID:
29651118
5.

Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy.

Rakocevic G, Martinez-Outschoorn U, Dalakas MC.

Neurol Neuroimmunol Neuroinflamm. 2018 Apr 5;5(4):e460. doi: 10.1212/NXI.0000000000000460. eCollection 2018 Jul. No abstract available.

6.

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.

Dalakas MC.

Ther Adv Neurol Disord. 2018 Jan 15;11:1756285617746640. doi: 10.1177/1756285617746640. eCollection 2018. Review.

7.

Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy.

Dalakas MC.

Lancet Neurol. 2018 Jan;17(1):20-21. doi: 10.1016/S1474-4422(17)30379-4. Epub 2017 Nov 6. No abstract available.

PMID:
29122522
8.

Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost.

Dalakas MC.

Ther Adv Neurol Disord. 2017 Aug;10(8):293-296. doi: 10.1177/1756285617717155. Epub 2017 Jun 28. No abstract available.

9.

A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome.

Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B.

Ann Neurol. 2017 Aug;82(2):271-277. doi: 10.1002/ana.25002. Epub 2017 Aug 9.

10.

Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors.

Dalakas MC.

J Neurol Sci. 2017 Jun 15;377:224-226. doi: 10.1016/j.jns.2017.04.016. Epub 2017 Apr 13. No abstract available.

PMID:
28477700
11.

Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease.

Fouka P, Alexopoulos H, Chatzi I, Dedos SG, Samiotaki M, Panayotou G, Politis P, Tzioufas A, Dalakas MC.

Neurol Neuroimmunol Neuroinflamm. 2016 Dec 5;4(1):e306. eCollection 2017 Jan.

12.

Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business.

Dalakas MC.

Neurology. 2016 Jul 26;87(4):350-1. doi: 10.1212/WNL.0000000000002796. Epub 2016 Jun 29. No abstract available.

PMID:
27358340
13.

Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis.

Dalakas MC.

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1037. doi: 10.1136/jnnp-2016-313418. Epub 2016 May 5. No abstract available.

PMID:
27151962
14.

Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.

Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J.

BMC Neurol. 2016 Apr 16;16:48. doi: 10.1186/s12883-016-0568-5.

15.

Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations.

Kampylafka EI, Alexopoulos H, Fouka P, Moutsopoulos HM, Dalakas MC, Tzioufas AG.

Lupus. 2016 Oct;25(11):1260-5. doi: 10.1177/0961203316636473. Epub 2016 Feb 27.

PMID:
26923281
16.

Close to the node but far enough: What nodal antibodies tell us about CIDP and its therapies.

Dalakas MC, Gooch C.

Neurology. 2016 Mar 1;86(9):796-7. doi: 10.1212/WNL.0000000000002427. Epub 2016 Feb 3. No abstract available.

PMID:
26843563
17.

Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab.

Magira EE, Alexopoulos H, Charitatos E, Michas D, Dalakas MC.

Ther Adv Neurol Disord. 2016 Jan;9(1):69-73. doi: 10.1177/1756285615614812. No abstract available.

18.

Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.

Dalakas MC.

Neurotherapeutics. 2016 Jan;13(1):1-3. doi: 10.1007/s13311-015-0414-2. No abstract available.

19.

Viruses in IBM: Hit-and-run, hide and persist, or irrelevant?

Dalakas MC, Schmidt J.

Neurology. 2016 Jan 19;86(3):204-5. doi: 10.1212/WNL.0000000000002295. Epub 2015 Dec 18. No abstract available.

PMID:
26683647
20.

Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease.

Alexopoulos H, Kampylafka EI, Fouka P, Tatouli I, Akrivou S, Politis PK, Moutsopoulos HM, Tzioufas AG, Dalakas MC.

J Neuroimmunol. 2015 Dec 15;289:8-11. doi: 10.1016/j.jneuroim.2015.10.007. Epub 2015 Oct 13.

PMID:
26616866

Supplemental Content

Loading ...
Support Center